Home -> Law Blog Directory -> Patent Law Blogs -> Patently Obvious
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense
Find a Local Lawyer
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402
Patent Law
: Patently ObviousBPAI Revised Procedure for Appeal Brief Review
By Dennis Crouch, Esq.
As part of the PTO's efforts to streamline appeal practice, the office has (internally) announced a new procedure for reviewing appeal brief formalities. Notably, the BPAI has been given the "sole responsibility" for determining whether appeal briefs are in compliance with the formalities required by 37 CFR 41.37. The USPTO has also indicated briefs will be accepted even if they contain "minor informalities" so long as those informalities do not affect the BPAI's decisionmaking ability.
The BPAI will review each opening brief before forwarding the brief to the examiner for consideration. Once the brief is accepted by the BPAI, neither the examiner nor the Patent Appeal Center will have any power to later reject the brief as non-compliant. The non-compliance form paragraphs are also being removed from the examiner's OACS computing system.
In a 2007 study of the prosecution files of 720 cases on appeal, I found that a full 25% had been rejected as 'defective' based on formalities. [Link]. A major purpose behind this power-shift is to reduce this paperwork churning and to create more uniformity in appeal processing. This shift also allows the BPAI to collect better data on the number and types of appeals being filed.
The announcement is signed by Bob Bahr, Associate Patent Commissioner (for patent examination policy).
File Attachment: bpai_revised_procedure_20100329.pdf (217 KB)
* * * *
The chart below shows the backlog of ex party BPAI appeals (excluding reexaminations).

The BPAI will be holding a roundtable on April 7.
Full post as published by Patently Obvious on April 02, 2010 (boomark / email).
Philip Morris
Loses Appeal, Will Pay Millions
Asbestos Mesothelioma Victim Wins Appeal of $20 Million Asbestos Cancer Verdict
Asbestos Mesothelioma Victim Wins Appeal of $20 Million Asbestos Cancer Verdict
FDA Issues Update on Safety Review Orlistat
Orlistat FDA Issues Update on Safety Review
Aurora Loan Faces Class Action over Mortgage Review Services
Aurora Loan Faces Class Action over Mortgage Review Services
FDA Review of Prostate Cancer Treatment Prompts Warning of Risk for Diabetes
Prostate Cancer Treatment FDA Review Prompts Warning of Risk for Diabetes
Xigris
Study Prompts FDA Safety Review

Practice Reminder - New BPAI Rules Take Effect December 10, 2008.
BPAI Appeal Brief Rules Delayed, According to Last-Minute PTO Notice
USPTO: It's OK To Start Filing Appeal Briefs Under New Format
USPTO publishes new rules for ex parte appeals before the BPAI
Effective date of new BPAI appeal rules delayed pending completion of OMB review
BPAI Raises Stakes for In Re Bilksi and the Future of Software Patents








